NCT02321592View on ClinicalTrials.gov

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2019

Study Completion Date

July 31, 2020

Conditions
Hodgkin Lymphoma
Interventions
DRUG

AFM13

Trial Locations (1)

Unknown

1st Department of Medicine, Cologne University Hospital, Cologne

Sponsors

Collaborators (1)

Affimed GmbH
All Listed Sponsors
collaborator

Affimed GmbH

INDUSTRY

collaborator

The Leukemia and Lymphoma Society

OTHER

lead

University of Cologne

OTHER